New
HealthMore in Health →
Intellia’s Phase 3 Result Marks a Turning Point for In Vivo CRISPR Medicine
Intellia has reported what the source material describes as the first Phase 3 success for an in vivo CRISPR therapy, a milestone that could move gene editing inside the body closer to regulatory approval.
Key Takeaways
- Intellia’s in vivo CRISPR therapy reportedly succeeded in a Phase 3 trial.
- The result is described as a first for an in vivo CRISPR treatment.
DE
DT Editorial AI··via endpoints.news